Production and characterization of a CD25-specific scFv-Fc antibody secreted from Pichia pastoris

Applied Microbiology and Biotechnology

Volumn 97, Issue 9, 2013, Pages 3855-3863

  Wan, Lin ^a   Zhu, Shengyun ^a   Zhu, Jian ^a   Yang, Hao ^a   Li, Shengfu ^a   Li, Youping ^a   Cheng, Jingqiu ^a   Lu, Xiaofeng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antibody engineering; CD25; Immunotherapy; P. pastoris; Single chain variable fragment

Indexed keywords

CELL PROLIFERATION; CELLS; CHAINS; CLONING; CYTOLOGY; CYTOTOXICITY; DIMERS; DISEASES; GENE ENCODING; LYMPHOCYTES; MOBILE SECURITY; T-CELLS; YEAST;

ANTIBODY ENGINEERING; CD25; IMMUNOTHERAPY; P. PASTORIS; SINGLE CHAIN VARIABLE FRAGMENTS;

ANTIBODIES;

ANTINEOPLASTIC AGENT; CONCANAVALIN A; DIMER; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE IMMUNOGLOBULIN G1 FC FRAGMENT ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY; IMMUNE RESPONSE; IMMUNOASSAY; YEAST;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER IMMUNOTHERAPY; CELL CLONING; COMPARATIVE STUDY; CONTROLLED STUDY; DEGLYCOSYLATION; FUSION GENE; HUMAN; IMMUNE RESPONSE; K562 CELL LINE; KOMAGATAELLA PASTORIS; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOLECULAR WEIGHT; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL LINE; GEL CHROMATOGRAPHY; GENETICS; IMMUNOLOGY; METABOLISM; PICHIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

PICHIA PASTORIS;

BLOTTING, WESTERN; CELL LINE; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; PICHIA; SINGLE-CHAIN ANTIBODIES;

EID: 84885922197     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4632-9     Document Type: Article

References (29)

1. Beck A, Wurch T, Bailly B, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345-352
2. Bielekova B, Becker BL (2010) Monoclonal antibodies in MS: mechanisms of action. Neurology 74(Suppl 1):S31-S40
3. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single-chain antigen-binding proteins. Science 242(4877):423-426
4. Campara M, Tzvetanov IG, Oberholzer J (2010) Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther 10(6):959-969
5. Colice GL (2011) Emerging therapeutic options for asthma. Am J Manage Care 17(Suppl 3):S82-S89
6. Feige MJ, Hendershot LM, Buchner J (2010) How antibodies fold. Trends Biochem Sci 35(4):189-198
7. Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer L, La Cava A, Shi FD (2011) Interleukin-2/ interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol 69 (4):721-734
8. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214-221
9. Ishida T, Ueda R (2011) Antibody therapy for adult T-cell leukemia-lymphoma. Int J Hematol 94(5):443-452
10. Jacobs PP, Geysens S, Vervecken W, Contreras R, Callewaert N (2009) Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat Protoc 4:58-70
11. Kaneko E, Niwa R (2011) Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs 25(1):1-11
12. Kontermann RE (2009) Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23(2):93-109
13. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N (2009) Engineered therapeutic antibodies with improved effector functions. Cancer Sci 100(9):1566-1572
14. Larson T, Nussenblatt RB, Sen HN (2011) Emerging drugs for uveitis. Expert Opin Emerg Drugs 16(2):309-322
15. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM (2010) An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 37(8):1529-1538
16. Martin R (2012) Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 142(1):9-14
17. Martin JF, Perry JS, Jakhete NR,Wang X, Bielekova B (2010) An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 185(2):1311-1320
18. McAuley A, Jacob J, Kolvenbach CG, Westland K, Lee HJ, Brych SR, Rehder D, Kleemann GR, Brems DN, Matsumura M (2008) Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci 17(1):95-106
19. Mottershead M, Neuberger J (2007) Daclizumab. Expert Opin Biol Ther 7(10):1583-1596
20. Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM (2009) Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 50(9):1500-1508
21. Rülker T, Voß L, Thullier P, O'Brien LM, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dübel S, Marschall HJ, Hust M, Hülseweh B (2012) Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One 7(5):e37242
22. Sanz L, Blanco B, Alvarez-Vallina L (2004) Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol 25(2):85-91
23. Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, Esteves IT, Behrens CK, Fournes B, Fournier N, de Romeuf C, Hust M, Dübel S (2011) Rise and fall of an anti-MUC1 specific antibody. PLoS One 6(1):e15921
24. Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27(1):1-18
25. Wan L, Cai H, Yang H, Lu Y, Li Y, Li X, Li S, Zhang J, Li Y, Cheng J, Lu X (2008) High-level expression of a functional humanized single-chain variable fragment antibody against CD25 in Pichia pastoris. Appl Microbiol Biotechnol 81(1):33-41
26. Wan L, Zhu S, Li Y, Liu S, Yang H, Li S, Li Y, Cheng J, Lu X (2011) Production and characterization of LEA29Y, a variant of cytotoxic T-lymphocyte antigen 4-immunoglobulin, in Pichia pastoris. Appl Microbiol Biotechnol 91(3):543-551
27. Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, Favole A, Tsuchikawa T, Silver S, Watkins SC, Kageshita T, Ferrone S (2011) Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 71(24):7410-7422
28. Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B (2011) A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 17(5):604-609
29. Yuasa N, Ogawa H, Koizumi T, Tsukamoto K, Matsumoto-Takasaki A, Asanuma H, Nakada H, Fujita-Yamaguchi Y (2012) Construction and expression of anti-Tn-antigen-specific single-chain antibody genes from hybridoma producing MLS128 monoclonal antibody. J Biochem 151(4):371-381